Document is current
Any future updates will be listed below
-
Authors
Dewor, Robert
Dabrowski, Michal J.
Więcek, Łukasz
Amtmański, Wojciech
Woszczek, Wojciech
Mróz, Mikołaj
Turczyn, Paweł
Helbig, Grzegorz
Węglarz, Patryk
Fornagiel, Szymon
Krzanowski, Jacek
Stach-Nowosiad, Katarzyna
Sobas, Marta
Szukalski, Łukasz
Markiewicz, Mirosław
Kot, Sylwia
Gala-Błądzińska, Agnieszka
Bróż, Sebastian
Piszcz, Jarosław
Leończuk, Natalia
Homenda, Wojciech
Rutkowska, Anita
Lasoń, Anna
Meryn, Anna
Jurczuk, Aleksandra
Konopelko, Michał
Bator, Aleksandra
Marciniak, Kinga
Dudziński, Marek
Dubiela, Paweł
Lis, Karol
Basak, Grzegorz
-
Funding
Funding for this research was provided by:
AstraZeneca Pharma Poland
- License Information
-
More Information
Article History
Received: 12 December 2025
Accepted: 29 June 2026
First Online: 9 July 2026
Competing interests
: R.D. is an employee and shareholder of AstraZeneca. P.D. is an employee of AstraZeneca. K.L., M.D., G.B. are the shareholders of Saventic Health. M.J.D., G.B., P.T. received honoraria from Saventic Health. A.G.-B. received paid expert testimony from AstraZeneca. L.W., W.A., W.W., M.M.roz, A.R., A.L., A.M., A.J., M.K., A.B., K.M., M.D., K.L. are employees of Saventic Health. G.H., P.W., S.F., J.K., K.S.-N., M.S., L.S., M.M., S.K., S.B., J.P., N.L., W.H. declare no competing financial or non-financial interests.
